Compliance Rate
Compliance Rate
36.36%
Compliant submissions
8
Incompliant submissions
14
Total trials
22
My Organizations' Clinical Trials
Showing 775 of 1641 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/01/19
End: 10/31/25
Due: 10/31/26
Phase: N/A
Priority: Normal
Start: 12/01/21
End: 04/01/25
Due: 04/01/26
Phase: N/A
Priority: Normal
Start: 08/31/08
End: 03/31/09
Due: 03/31/10
Phase: N/A
Priority: Normal
Start: 06/30/15
End: 06/05/19
Due: 06/05/20
Phase: N/A
Priority: Normal
Start: 08/31/13
End: 08/31/19
Due: 08/31/20
Phase: N/A
Priority: Normal
Start: 11/15/20
End: 06/29/21
Due: 06/29/22
Phase: N/A
Priority: Normal
Start: 05/24/18
End: 10/30/18
Due: 10/30/19
Phase: N/A
Priority: Normal
Start: 08/31/21
End: 01/26/22
Due: 01/26/23
Phase: N/A
Priority: Normal
Start: 06/30/19
End: 12/31/22
Due: 12/31/23
Phase: N/A
Priority: Normal
Start: 03/20/23
End: 06/30/24
Due: 06/30/25
Phase: N/A
Priority: Normal
Start: 06/30/11
End: 06/30/17
Due: 06/30/18
Phase: N/A
Priority: Normal
Start: 09/30/03
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 12/31/09
End: 01/31/14
Due: 01/31/15
Effect of the LIVESTRONG at the YMCA Exercise Program on Cancer Related Outcomes in Cancer Survivors
Phase: N/A
Priority: Normal
Start: 02/28/13
End: 12/31/15
Due: 12/31/16
Phase: N/A
Priority: Normal
Start: 05/11/17
End: 12/11/19
Due: 12/11/20
Phase: N/A
Priority: Normal
Start: 02/28/13
End: 03/31/15
Due: 03/31/16
Phase: N/A
Priority: Normal
Start: 06/28/25
End: 10/01/25
Due: 10/01/26
Phase: N/A
Priority: Normal
Start: 09/30/16
End: 09/30/21
Due: 09/30/22
Phase: N/A
Priority: Normal
Start: 05/31/95
End: 04/30/00
Due: 04/30/01
Phase: N/A
Priority: Normal
Start: 05/31/16
End: 05/31/17
Due: 05/31/18
Phase: N/A
Priority: Normal
Start: 07/02/24
End: 05/31/25
Due: 05/31/26
Phase: N/A
Priority: Normal
Start: 10/20/25
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 11/15/19
End: 07/31/21
Due: 07/31/22
Phase: N/A
Priority: Normal
Start: 10/19/20
End: 09/06/21
Due: 09/06/22
Phase: N/A
Priority: Normal
Start: 07/31/10
End: 11/30/13
Due: 11/30/14